CCM
BLACR

Condor Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Condor Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,400
Closed -$1.41K – 201
2024
Q1 		$1.41K Hold
10,400
– – ﹤0.01% 183
2023
Q4 		$1.4K Buy
+10,400
New +$1.68K ﹤0.01% 194

Other funds holding BLACR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Condor Capital Management's BLACR Position: Q2 2024 in Review

Condor Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q2 2024, closing a stake of 10,400 shares — an estimated $1.41K sold.

Condor Capital Management first reported a position in BLACR in Q4 2023 and held it in 2 quarters. The position peaked at $1.41K in Q1 2024. 30 funds tracked by Wall St. Rank hold BLACR as of Q2 2024.

  • Condor Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q2 2024 after selling out during the quarter.
  • Condor Capital Management sold 10,400 Bellevue Life Sciences Acquisition Corp. Rights shares in Q2 2024, an estimated $1.41K.
  • Condor Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 2 quarters.
  • Condor Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $1.41K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q2 2024.

Based on Condor Capital Management's 13F filing for Q2 2024, filed 8 Aug 2024.